Gerarda Mastrogiorgio

Gerarda Mastrogiorgio

Auto-generated profile, based on publicly available information

Gerarda Mastrogiorgio

Bambino Gesu Childrens Hosp Rome, IRCCS, Rare Dis & Med Genet, Rome, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
GMGerarda Mastrogiorgio
Gerarda Mastrogiorgio
MMMarina Macchiaiolo
Marina Macchiaiolo
PBPaola Sabrina Buonuomo
Paola Sabrina Buonuomo
EBEmanuele Bellacchio
Emanuele Bellacchio
MBMatteo Bordi
Matteo Bordi
ABAndrea Bartuli
Andrea Bartuli
Background: Adenylosuccinate lyase deficiency (ADSLD) is an ultrarare neurometabolic recessive disorder caused by loss-of-function mutations in the ADSL gene. The disease is characterized by wide clinical variability. Here we provide an updated clinical profiling of the disorder and discuss genotype–phenotype correlations. Results: Data were collected through "Our Journey with ADSL deficiency Association" by using a dedicated web survey filled-in by parents. Clinical and molecular data were collected from 18 patients (12 males, median age 10.9 years ± 7.3), from 13 unrelated families. The age at onset ranged from birth to the first three years (median age 0.63 years ± 0.84 SD), and age at diagnosis varied from 2 months to 17 years, (median age 6.4 years ± 6.1 SD). The first sign was a psychomotor delay in 8/18 patients, epilepsy in 3/18, psychomotor delay and epilepsy in 3/18, and apneas, hypotonia, nystagmus in single cases. One patient (sibling of a previously diagnosed child) had a presymptomatic diagnosis. The diagnosis was made by exome sequencing in 7/18 patients. All patients were definitively diagnosed with ADSL deficiency based on pathogenic variants and/or biochemical assessment. One patient had a fatal neonatal form of ADSL deficiency, seven showed features fitting type I, and nine were characterized by a milder condition (type II), with two showing a very mild phenotype. Eighteen different variants were distributed along the entire ADSL coding sequence and were predicted to have a variable structural impact by impairing proper homotetramerization or catalytic activity of the enzyme. Six variants had not previously been reported. All but two variants were missense. Conclusions: The study adds more details on the spectrum of ADSLD patients’ phenotypes and molecular data.

1 December 2012 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Open access
RNRaffaella Nenna
Raffaella Nenna
FMFabio Massimo Magliocca
Fabio Massimo Magliocca
CTClaudio Tiberti
Claudio Tiberti
GMGerarda Mastrogiorgio
Gerarda Mastrogiorgio
LPLaura Petrarca
Laura Petrarca
MBMargherita Bonamico
Margherita Bonamico
Objectives: Lymphocytic gastritis (LG) has been reported in patients with celiac disease (CD). The aim of the present study was to evaluate gastric mucosa involvement in celiac children and gastroenterological controls (GC). Methods: In a retrospective study on 226 patients with CD (82 M; median age: 5.7years) at diagnosis and 154 GC (66 M; median age: 7.4 years), the evaluation of gastric and duodenal mucosa was performed. CD was diagnosed according to the North America Society for Pediatric Gastroenterology, Hepatology, and Nutrition criteria. Gastric lesions were classified according to Updated Sydney System. Anti-gastric parietal cell antibodies (GPCA) were assayed by enzyme-linked immunosorbent assay. Results: A total of 21.2% and 7% of patients with CD showed chronic superficial gastritis (CSG) and LG, respectively. Helicobacter pylori (Hp) infection was found in 6 (2.7%) children with CD (66.7% had CSG, 16.7% LG, and 16.7% interstitial gastritis). CSG was present in 21.4% of controls. No control subject showed LG. Hp infection was found in 24 (15.6%) children with GC (91.7% had CSG). Among patients with CSG, Hp infection was more frequent in controls than in celiac children (P < 0.0001). Ten of 90 patients with CD and 1 of 29 controls were positive for GPCA. Conclusions: Gastritis is a common finding in children with CD and adolescents. In celiac subjects, CSG is the most frequently detected. Our data suggest the hypothesis that LG may be related to a longer exposure to gluten. The presence of GPCA may suggest the presence of an underlying autoimmune process.

22 May 2018 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
PBPaola Sabrina Buonuomo
Paola Sabrina Buonuomo
MMMarina Macchiaiolo
Marina Macchiaiolo
GLGiovanna Leone
Giovanna Leone
PVPaola Valente
Paola Valente
GMGerarda Mastrogiorgio
Gerarda Mastrogiorgio
ABAndrea Bartuli
Andrea Bartuli
Homozygous familial hypercholesterolaemia is a rare life-threatening disease characterized by markedly elevated low-density lipoprotein cholesterol (LDL-C) concentrations and accelerated atherosclerosis. The presence of double gene defects in the LDL-Receptor, either the same defect (homozygous) or two different LDL-raising mutations (compound heterozygotes) or other variants, identify the homozygous phenotype (HopFH). Apheresis is a procedure in which plasma is separated from red blood cells before the physical removal of LDL-C or the LDL-C is directly removed from whole blood. It is currently the treatment of choice for patients with HopFH whose LDL-C levels are not able to be reduced to target levels with conventional lipid-lowering drug therapy. The aim of this study is to report a cohort of six paediatric patients and to evaluate the long term efficacy of combined medical therapy and LDL-apheresis on LDL-C reduction. We collected data from six children with confirmed diagnosis of HopFH (two females and four males; age range at diagnosis 3–8 years, mean 6 ± 1 years) from a single clinical hospital in Italy from 2007 to 2017. Clinical manifestations and outcomes may greatly vary in children with HopFH. Medical therapy and LDL-apheresis for the severe form should be started promptly in order to prevent cardiovascular disease. Lipoprotein apheresis is a very important tool in managing patients with HopFH at high risk of cardiovascular disease. Based on our experience and the literature data, the method is feasible in very young children, efficient regarding biological results and cardiac events, and safe with minor side-effects and technical problems. We advise treating homozygous and compound heterozygous children as soon as possible.

1 December 2017 in The Journal of Pediatrics
Verified
Journal Article
Open access
PBPaola Sabrina Buonuomo
Paola Sabrina Buonuomo
MMMarina Macchiaiolo
Marina Macchiaiolo
GMGerarda Mastrogiorgio
Gerarda Mastrogiorgio
IRIppolita Rana
Ippolita Rana
MGMichaela Veronika Gonfiantini
Michaela Veronika Gonfiantini
ABAndrea Bartuli
Andrea Bartuli

28 March 2021 in Atherosclerosis
Verified
Journal Article
Closed access
PDF file
PBPaola Sabrina Buonuomo
Paola Sabrina Buonuomo
GMGerarda Mastrogiorgio
Gerarda Mastrogiorgio
GLGiovanna Leone
Giovanna Leone
IRIppolita Rana
Ippolita Rana
MGMichaela Veronika Gonfiantini
Michaela Veronika Gonfiantini
ABAndrea Bartuli
Andrea Bartuli

18 September 2020 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
MMMarina Macchiaiolo
Marina Macchiaiolo
FPFilippo Maria Panfili
Filippo Maria Panfili
MGMichaela Veronika Gonfiantini
Michaela Veronika Gonfiantini
GMGerarda Mastrogiorgio
Gerarda Mastrogiorgio
PBPaola Sabrina Buonuomo
Paola Sabrina Buonuomo
ABAndrea Bartuli
Andrea Bartuli